Duesseldorf

• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• Proof-of-concept study for SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP) Ended
  2024-512345-16-00 4 2021-10-13 Chronic inflammatory demyelinating polyradiculoneuropathy
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 4 2021-09-13 Advanced solid tumors
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Ended
  2024-513313-13-00 9 2020-12-09 Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndro
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef … Ended
  2023-507897-42-00 4 2020-05-12 Prevention of oesophageal strictures in adult patients after endoscopi
• An extension study of Dasiglucagon in children with CHI Ended
  2024-514007-34-00 5 2020-03-08 Children with congenital hyperinsulinism
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertensi … Ended
  2023-504601-36-00 5 2019-11-20 Open-angle Glaucoma
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progen … Ended
  2024-516894-57-00 5 2018-09-07 Transfusion-dependent β-thalassemia (TDT)
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PAT … Ended
  2024-519350-37-00 4 patients with unresectable or metastatic HER2 negative breast cancer a

Showing 361–382 of 382 trials